Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 4/20 | 0.53 |
| ▸ | BDNF | P23560 | 3/20 | 0.53 |
| ▸ | PTN | P21246 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.41 |
| ▸ | FGF1 | P05230 | 2/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | FGF2 | P09038 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30341681 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL31556472 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL31067715 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL31067693 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL932879 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL24484198 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL6748051 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL20516492 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL22071113 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 | |
| SCHEMBL29459916 | 1.00 | MDK (0.53) | MDKBDNFPTNMAPK1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243326-A1 | METHOD OF PREPARING A HYDROGEL PRODUCT | Galderma Holding SA (CH) | 2025-07-31 | — | — | US | claimed |
| EP-3897763-B1 | HYDROGEL COMPOSITIONS ENCAPSULATING SOLID PARTICLES | Galderma Holding SA (CH) | 2025-04-09 | — | — | EP | claimed |
| US-12252594-B2 | Method of preparing a hydrogel product | Galderma Holding SA (CH) | 2025-03-18 | — | — | US | claimed |
| CN-119409745-A | Preparation method of hyaluronic acid oligosaccharide with controllable polymerization degree and derivatives thereof | 山东大学 | 2025-02-11 | — | — | CN | claimed |
| CN-119020338-A | Hyaluronic acid lyase and application thereof in degradation of hyaluronic acid | 江南大学 | 2024-11-26 | — | — | CN | claimed |
| CN-118406592-A | Microorganism and application thereof | 北京华妍生物科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-118345066-A | Glycosaminoglycan lyase and application thereof | 北京华妍生物科技有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-114574532-B | Preparation method of hyaluronic acid di-tetra-hexasaccharide | 水羊化妆品制造有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-118028270-A | Glycosaminoglycan degrading enzyme and application thereof | 北京华妍生物科技有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-115873144-B | Acetylated small-molecule sodium hyaluronate and preparation method and application thereof | 水羊化妆品制造有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-20220380488-A1 | ULTRA-LOW MOLECULAR WEIGHT HYALURONIC ACID AND PREPARATION METHOD THEREFOR | Nanjing Letop Biotechnology Co., Ltd. (CN) | 2022-12-01 | — | — | US | claimed |
| CN-217844576-U | Device for drying ultralow molecular hyaluronic acid tetrasaccharide and hexasaccharide | 南京微构医药科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-217838986-U | Device for separating ultralow molecular hyaluronic acid tetrasaccharide and hexasaccharide | 南京微构医药科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-114901701-A | Ultra-low molecular weight hyaluronic acid and preparation method thereof | 南京汉欣医药科技有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-114767649-A | Preparation of cis-hyaluronic acid hexasaccharide and preparation method thereof | 北京佗林医药科技有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-11389567-B2 | Injectable gel product | GALDERMA HOLDINGS SA (CH) | 2022-07-19 | — | — | US | claimed |
| CN-114574532-A | Preparation method of hyaluronic acid ditetrahexaose | 水羊化妆品制造有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114350728-A | Method for preparing hyaluronic acid oligosaccharide by enzyme method | 华熙生物科技股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114316085-A | Cis-hyaluronic acid hexasaccharide and preparation method and application thereof | 北京佗林医药科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-114288308-A | Hyaluronic acid oligosaccharide composition mainly containing tetrasaccharide and preparation method and application thereof | 华熙生物科技股份有限公司 | 2022-04-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380488-A1 | ULTRA-LOW MOLECULAR WEIGHT HYALURONIC ACID AND PREPARATION METHOD THEREFOR | CD44, MMP1, MMP2 | MDK 1832/4885BDNF 1192/4885PTN 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.